Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals Ownership Summary
Zentalis Pharmaceuticals is owned by 81.55% institutional investors, 13.39% insiders, and 5.07% retail investors. Matrix capital management company, lp is the largest institutional shareholder, holding 19.63% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.
ZNTL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Zentalis Pharmaceuticals | 81.55% | 13.39% | 5.07% |
| Sector | Healthcare Stocks | 279.19% | 10.62% | -189.81% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Matrix capital management company, lp | 13.96M | 19.63% | $42.30M |
| Blackrock | 4.82M | 6.80% | $19.71M |
| Blackrock funding, inc. /de | 4.24M | 5.96% | $12.84M |
| Vanguard group | 3.27M | 4.60% | $9.91M |
| State street | 3.05M | 4.31% | $12.48M |
| Decheng capital | 2.34M | 3.29% | $7.08M |
| Morgan stanley | 1.95M | 2.75% | $7.98M |
| Opaleye management | 1.77M | 2.49% | $5.36M |
| Almitas capital | 1.63M | 2.29% | $4.93M |
| Primecap management co/ca/ | 1.52M | 2.14% | $4.61M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mayo clinic | 187.14K | 25.27% | $765.41K |
| Matrix capital management company, lp | 13.96M | 1.97% | $42.30M |
| Decheng capital | 2.34M | 1.52% | $7.08M |
| Almitas capital | 1.63M | 1.08% | $4.93M |
| Opaleye management | 1.77M | 0.94% | $5.36M |
| Tybourne capital management (hk) | 961.49K | 0.73% | $2.91M |
| 5am venture management | 490.00K | 0.35% | $1.48M |
| Anfield capital management | 129.32K | 0.14% | $391.83K |
| Pfizer | 953.83K | 0.11% | $2.89M |
| Boxer capital | 450.00K | 0.10% | $1.84M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Pfizer | 953.83K | 0.11% | 953.83K |
| Morgan stanley | 1.95M | 0.00% | 913.31K |
| Acadian asset management | 1.07M | 0.01% | 804.02K |
| Opaleye management | 1.77M | 0.94% | 800.50K |
| Almitas capital | 1.63M | 1.08% | 665.97K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 182.31K | - | -4.89M |
| Eventide asset management | - | - | -4.48M |
| Vanguard group | 3.27M | 0.00% | -1.34M |
| T. rowe price investment management | - | - | -1.33M |
| Bioimpact capital | - | - | -1.11M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Pfizer | 953.83K | 0.11% | 953.83K | $2.89M |
| Cubist systematic strategies | 180.22K | 0.00% | 180.22K | $546.08K |
| Bnp paribas arbitrage, snc | 176.29K | 0.00% | 176.29K | $534.16K |
| Bridgeway capital management | 175.00K | 0.01% | 175.00K | $530.25K |
| Ameriprise financial | 146.67K | 0.00% | 146.67K | $444.42K |
Sold Out
| Holder | Change |
|---|---|
| Gamma investing | -2.00 |
| Farther finance advisors | -10.00 |
| Nelson, van denburg & campbell wealth management group | -11.00 |
| Ifp advisors | -23.00 |
| Riggs asset managment | -23.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 134 | -8.22% | 58,450,755 | -9.27% | 81 | 0.99% | 60 | -34.07% | 49 | 63.33% |
| Dec 31, 2024 | 139 | 0.72% | 61,824,330 | -12.88% | 86 | 0.87% | 85 | 19.72% | 28 | -26.32% |
| Sep 30, 2024 | 137 | -4.86% | 70,963,212 | -7.43% | 99 | 0.85% | 71 | -13.41% | 38 | -5.00% |
| Jun 30, 2024 | 144 | 2.13% | 76,655,527 | -9.95% | 108 | 0.75% | 82 | 5.13% | 40 | 11.11% |
| Mar 31, 2024 | 141 | 14.63% | 85,130,112 | 5.09% | 120 | 0.92% | 78 | 20.00% | 36 | 12.50% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 2.83M | 3.96% | -2.12M |
| Vanguard US Total Market Shares ETF | 1.89M | 2.64% | - |
| Eventide Gilead N | 1.64M | 2.30% | -1.94M |
| Vanguard Total Stock Mkt Idx Inv | 1.58M | 2.19% | - |
| iShares Russell 2000 ETF | 1.52M | 2.12% | 747.00 |
| Fidelity Growth Compy Commingled Pl O | 1.16M | 1.63% | - |
| PRIMECAP Odyssey Aggressive Growth | 913.40K | 1.27% | -216.11K |
| FIAM Small Cap Core CIT Cl B | 886.80K | 1.25% | 11.50K |
| Vanguard Institutional Extnd Mkt Idx Tr | 896.55K | 1.25% | - |
| Fidelity Growth Compy Commingled Pl S | 881.46K | 1.24% | -280.77K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Apr 30, 2025 | Myers Scott Dunseth | - | Buy | $29.37K |
| Feb 06, 2025 | Bruns Ingmar | Chief Medical Officer | Buy | $45.66K |
| Feb 03, 2025 | Vultaggio Vincent | PAO and Interim PFO | Sell | $4.48K |
| Feb 03, 2025 | Lackner Mark | Chief Scientific Officer | Sell | $24.59K |
| Feb 03, 2025 | Paul Andrea | Chief Legal Officer | Sell | $22.64K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | 1 | - |
| 2025 Q1 | 4 | 4 |
| 2024 Q4 | - | 1 |
| 2024 Q2 | - | 2 |
| 2024 Q1 | - | 6 |
ZNTL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools